Luca Issi
Stock Analyst at RBC Capital
(1.37)
# 3,376
Out of 4,865 analysts
199
Total ratings
38.4%
Success rate
-15.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $5 → $4 | $2.32 | +72.41% | 8 | May 15, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Outperform | $10 | $1.30 | +669.23% | 9 | May 14, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $21 → $18 | $17.76 | +1.35% | 7 | May 8, 2025 | |
| MRNA Moderna | Maintains: Sector Perform | $32 → $28 | $25.55 | +9.59% | 14 | May 2, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $205 → $210 | $172.90 | +21.46% | 2 | May 2, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $24 → $20 | $3.92 | +410.20% | 5 | Mar 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $310 → $330 | $308.71 | +6.90% | 27 | Mar 21, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $105 → $95 | $12.60 | +653.97% | 7 | Mar 19, 2025 | |
| SGMO Sangamo Therapeutics | Reiterates: Sector Perform | $2 | $0.48 | +313.99% | 6 | Mar 18, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | $17 | $8.30 | +104.82% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $6.36 | +104.40% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $15 | $11.38 | +31.81% | 7 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $4.15 | +743.37% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $16.67 | +55.97% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $36.15 | +93.64% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $55.00 | +27.27% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $53 → $48 | $43.19 | +11.14% | 13 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $15.50 | +170.97% | 8 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $14.79 | +62.27% | 6 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $36.08 | +57.98% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $8.66 | +246.42% | 9 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $29.34 | +128.36% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $45 | $10.86 | +314.36% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.14 | +86.92% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $36.66 | +110.04% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $6.59 | +127.62% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $54 | $9.58 | +463.67% | 4 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.16 | +1,106.90% | 5 | Aug 7, 2024 |
Adverum Biotechnologies
May 15, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.32
Upside: +72.41%
Allogene Therapeutics
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.30
Upside: +669.23%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $17.76
Upside: +1.35%
Moderna
May 2, 2025
Maintains: Sector Perform
Price Target: $32 → $28
Current: $25.55
Upside: +9.59%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $205 → $210
Current: $172.90
Upside: +21.46%
Lexeo Therapeutics
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $3.92
Upside: +410.20%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Outperform
Price Target: $310 → $330
Current: $308.71
Upside: +6.90%
Korro Bio
Mar 19, 2025
Maintains: Outperform
Price Target: $105 → $95
Current: $12.60
Upside: +653.97%
Sangamo Therapeutics
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.48
Upside: +313.99%
Ocular Therapeutix
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $8.30
Upside: +104.82%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $6.36
Upside: +104.40%
Mar 4, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $11.38
Upside: +31.81%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $4.15
Upside: +743.37%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $16.67
Upside: +55.97%
Feb 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $36.15
Upside: +93.64%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $55.00
Upside: +27.27%
Feb 12, 2025
Maintains: Sector Perform
Price Target: $53 → $48
Current: $43.19
Upside: +11.14%
Feb 11, 2025
Reiterates: Outperform
Price Target: $42
Current: $15.50
Upside: +170.97%
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $14.79
Upside: +62.27%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $36.08
Upside: +57.98%
Jan 21, 2025
Reiterates: Outperform
Price Target: $30
Current: $8.66
Upside: +246.42%
Jan 21, 2025
Reiterates: Outperform
Price Target: $67
Current: $29.34
Upside: +128.36%
Jan 14, 2025
Reiterates: Outperform
Price Target: $45
Current: $10.86
Upside: +314.36%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.14
Upside: +86.92%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $36.66
Upside: +110.04%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $6.59
Upside: +127.62%
Sep 19, 2024
Reiterates: Outperform
Price Target: $54
Current: $9.58
Upside: +463.67%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.16
Upside: +1,106.90%